Efficacy and safety of sildenafil in patients with congestive heart failure [7]

Archives of Internal Medicine

Volumn 164, Issue 18, 2004, Pages 2067-2068

  Mikhail, Nasser ^a  

^a OLIVE VIEW UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG SAFETY; ERECTILE DYSFUNCTION; HUMAN; LETTER; PRIORITY JOURNAL; SIDE EFFECT;

HEART FAILURE, CONGESTIVE; HUMANS; IMPOTENCE; MALE; PIPERAZINES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 6344253361     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Webster LJ, Michelakis ED, Davis T, Archer SL. Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial. Arch Intern Med. 2004;164:514-520.
2. Mulhall JP. Deciphering erectile dysfunction drug trials. J Urol. 2003;170:353-358.
3. Boulton AJM, Selam JL, Sweeny M, Ziegler D. Sildenafil citrate for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia. 2001;44:1296-1301.
4. Goldstein I, Lue TF, Padma-Nathan H, et al; the Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998;338:1397-1404.